Literature DB >> 3895535

Prostacyclin and thromboxane A2 moderate postischemic renal failure.

S Lelcuk, F Alexander, L Kobzik, C R Valeri, D Shepro, H B Hechtman.   

Abstract

Since prostacyclin (PGI2) is known to regulate renal cortical blood flow and since ischemia stimulates thromboxane (Tx) A2 synthesis, the role of these prostanoids in moderating the response to renal ischemia was studied in the rat. At baseline, plasma TxB2 concentration in untreated animals (n = 13) was 357 pg/ml. The left renal pedicle was clamped for 45 minutes after a right nephrectomy (n = 16), which led after 5 minutes of reperfusion to a rise in TxB2 to 2825 pg/ml (p less than 0.001), but there was no change in 6-keto-PGF1 alpha. After 24 hours creatinine levels rose from 0.4 to 3.0 mg/dl (p less than 0.001), and left renal weight rose from 94% to 117% (p less than 0.001) relative to the weight of the right kidney. In nephrectomized but nonischemic sham control rats (n = 7), creatinine level was 0.9 mg/dl and kidney weight 91% after 24 hours. Pretreatment with OKY 046 (n = 13) (2 mg/kg administered intravenously) blocked ischemia-induced TxB2 synthesis, while 6-keto-PGF1 alpha levels rose from 96 to 302 pg/ml (p less than 0.001). There was no increase in creatinine levels or kidney weight relative to the sham group. Pretreatment with ibuprofen (n = 10) (12 mg/kg) or OKY 046 and ibuprofen (n = 9) inhibited TxB2 and 6-keto-PGF1 alpha synthesis, but creatinine levels and renal weight rose (p less than 0.001). Renal histology in OKY 046-pretreated animals was equal to that in nephrectomized controls, while all other ischemic groups showed tubular necrosis. Results indicate that a high PGI2/TxA2 ratio protects against renal ischemia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3895535

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  13 in total

Review 1.  Cardiac transplantation. Selection, immunosuppression, and survival.

Authors:  L W Stevenson; H Laks; P I Terasaki; B D Kahan; D C Drinkwater
Journal:  West J Med       Date:  1988-11

2.  Noncardiogenic pulmonary edema after abdominal aortic aneurysm surgery.

Authors:  I S Paterson; J M Klausner; R Pugatch; P Allen; J A Mannick; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1989-02       Impact factor: 12.969

3.  Pharmacologic modulation of experimental postischemic hepatic function.

Authors:  S J Ontell; L Makowka; J Trager; V Mazzaferro; P Ove; T E Starzl
Journal:  Ann Surg       Date:  1989-02       Impact factor: 12.969

4.  Vasodilator prostaglandins (PG) prevent renal damage after ischemia.

Authors:  R P Kaufman; H Anner; L Kobzik; C R Valeri; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1987-02       Impact factor: 12.969

5.  The role of oxygen free radicals and prostaglandins in reperfusion injury to warm ischemic kidneys.

Authors:  A Greenstein; D Aravot; Z Braf; S Lelcuk
Journal:  Urol Res       Date:  1991

6.  The protective effect of thromboxane A2 synthetase inhibitor against ischemic liver injury.

Authors:  H Isozaki; K Okajima; H Hara; M Kobayashi
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

7.  Metabolism of prostaglandins in porcine liver transplantation with a graft harvested after 30- and 60-minute warm ischemia.

Authors:  H Isai; J Kimura; K Ito; M Tamura; H Kon; H Kamachi; M Takahashi; K Yamashita; T Shimamura; Y Nakajima
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

8.  Thromboxane A2 moderates permeability after limb ischemia.

Authors:  S Lelcuk; F Alexander; C R Valeri; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1985-11       Impact factor: 12.969

9.  Effects of a stable prostacyclin analog on experimental ischemic acute renal failure.

Authors:  M Tobimatsu; Y Ueda; S Saito; T Tsumagari; K Konomi
Journal:  Ann Surg       Date:  1988-07       Impact factor: 12.969

10.  The localization of thromboxane synthase in normal and pathological human kidney tissue using a monoclonal antibody Tü 300.

Authors:  R Nüsing; P M Fehr; F Gudat; E Kemeny; M J Mihatsch; V Ullrich
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.